TSHA

NASDAQ 已收盘

Taysha Gene Therapies

3.77 USD
▼-0.22-5.51%
盘后 3.74 -0.80%
2026-11-19
市值
$1.21B
市盈率
—
EPS
-0.42
股息率
—
52 周区间
3.46 – 7.30
成交量
2.18M
Beta
1.31
目标价
13.00
52W 低 3.4652W 高 7.30
价格走势

公司简介

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-...